PDT Partners’s CorMedix CRMD Stock Holding History

PDT Partners’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-28,649	Closed	-$81K	–	684
2022 Q3	$81K	Sell	28,649 -12,974	-31%	-$54K	0.01%	792
2022 Q2	$167K	Buy	41,623 +24,201	+139%	+$89.9K	0.01%	844
2022 Q1	$95K	Buy	+17,422	New	+$79.8K	0.01%	869

Other funds holding CRMD

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Spinnaker Capital Boston, Massachusetts $1.08M AUM 45.28% 1-Year Est. Return

PDT Partners's CRMD Position: Q4 2022 in Review

PDT Partners sold out of CorMedix (CRMD) in Q4 2022, closing a stake of 28,649 shares — an estimated $81K sold.

PDT Partners first reported a position in CRMD in Q1 2022 and held it in 3 quarters. The position peaked at $167K in Q2 2022. 65 funds tracked by Wall St. Rank hold CRMD as of Q4 2022.

PDT Partners reported no remaining CorMedix position as of Q4 2022 after selling out during the quarter.
PDT Partners sold 28,649 CorMedix shares in Q4 2022, an estimated $81K.
PDT Partners first reported a position in CorMedix in Q1 2022 and held it in 3 quarters.
PDT Partners's CorMedix position peaked at $167K in Q2 2022.
65 funds tracked by Wall St. Rank held CorMedix as of Q4 2022.

Based on PDT Partners's 13F filing for Q4 2022, filed 14 Feb 2023.